Short answer
Tenaya Therapeutics Inc (TNYA) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M with net income of −$19M.
Q3 2026 key financials · XBRL
- Revenue
- $2M
- +52.9% QoQ
- Net income
- −$19M
- +6.6% YoY · +56.4% QoQ
- Operating margin
- -1153.3%
- EPS (diluted)
- −$0.08
- +27.3% YoY · +60.0% QoQ
Source: XBRL data from the Tenaya Therapeutics Inc (TNYA) Q3 2026 10-Q on SEC EDGAR. USD.
Tenaya Therapeutics Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $1.7M, versus none YoY, entirely collaboration revenue
- Net loss $18.9M vs $20.3M YoY, operating loss $19.6M vs $20.9M
- Clinical R&D highest-performing category, $6.2M, up 52% YoY; manufacturing lowest, $1.5M, down 64%
- Cash and equivalents $66.8M at September 30, 2026; operating cash use $40.5M year-to-date
- Outlook: cash sufficient through at least next twelve months; pivotal-trial regulatory updates planned by year end
Risk Factors
- Newly added tax risk: California’s temporary state NOL suspension applies to taxable years 2024, 2025 and 2026
- Manufacturing risk: Closure of the GMMC may require comparability studies, regulatory filings and facility approvals for TN-201 and TN-401
- Regulatory risk: February 2026 legislation permits FDA approval of multiple versions of orphan drugs across subindications and subpopulations
- Operational risk: FDA placed MyPEAK-1 on clinical hold in November 2025, later lifted after protocol amendments
- Financial risk: Cash and cash equivalents totaled $66.8 million at September 30, 2026, against an accumulated deficit of $686.6 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.